Tirzepatide and Heart Failure (HFpEF): The SUMMIT Data

If you have read that tirzepatide (sold as Zepbound for obesity and Mounjaro for type 2 diabetes) "treats heart failure," the underlying trial is real and genuinely important — and, as usual, the headline runs slightly ahead of the regulatory facts. The honest version has two halves you have to hold together. In a randomized, placebo-controlled trial of people who had heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly lowered the risk of a worsening-heart-failure event or cardiovascular death, and meaningfully improved quality of life and walking distance. But as of this writing it is not FDA-approved for heart failure of any kind — the trial established a real clinical benefit in a specific population, not a new approved indication. This guide separates what the SUMMIT trial actually showed from what it did not, and keeps the line between trial benefit and approved use bright.

First, what HFpEF is — and why obesity matters here

Heart failure with preserved ejection fraction is the form of heart failure in which the heart squeezes normally (ejection fraction is preserved, typically ≥50%) but is stiff and fills poorly, so the body still gets congested — breathlessness, swelling, exercise intolerance. It is distinct from the "reduced ejection fraction" form that most older heart-failure drugs were built for, and for a long time HFpEF had few treatments with strong outcome data behind them.

Obesity is not incidental to this story; it is central to it. Excess weight is one of the strongest drivers of HFpEF, and there is a recognized "obesity phenotype" of the disease in which body fat, inflammation, and fluid overload combine to produce symptoms. That is exactly the population the SUMMIT trial set out to study — not heart failure in general, but HFpEF in people who also have obesity — which is both the trial's strength (a clear, mechanistically coherent target) and the boundary of what it can claim.

What the trial actually showed: SUMMIT

The evidence behind the "tirzepatide for heart failure" story is the SUMMIT trial, published in the New England Journal of Medicine in 2025¹. It is worth being precise about the design, because the design defines the claim.

SUMMIT was an international, double-blind, randomized, placebo-controlled trial. It enrolled 731 patients who had heart failure, an ejection fraction of at least 50%, and a body-mass index of at least 30, and randomly assigned them 1:1 to once-weekly tirzepatide (titrated up to 15 mg subcutaneously) or placebo for at least 52 weeks, on top of their existing heart-failure therapy. The median follow-up was about 104 weeks. There were two primary endpoints: a composite of adjudicated cardiovascular death or a worsening-heart-failure event, and the change at 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), a validated quality-of-life measure scored 0–100¹.

The results were positive on both primary endpoints¹:

• •The composite of cardiovascular death or worsening-heart-failure event occurred in 36 of 364 patients (9.9%) on tirzepatide versus 56 of 367 (15.3%) on placebo — a hazard ratio of 0.62 (95% CI, 0.41 to 0.95; P = 0.026).
• •That benefit was driven by worsening-heart-failure events, which fell from 14.2% on placebo to 8.0% on tirzepatide (hazard ratio 0.54; 95% CI, 0.34 to 0.85).
• •Quality of life improved more on tirzepatide: the KCCQ-CSS rose 19.5 points versus 12.7 on placebo, a between-group difference of 6.9 points (95% CI, 3.3 to 10.6; P < 0.001).

A pre-specified expanded analysis of the same trial, published in Circulation, added the functional-capacity picture: tirzepatide improved 6-minute walk distance by 18.3 meters versus placebo (95% CI, 9.9 to 26.7; P < 0.001), along with better scores on a general health-state index and a shift toward more favorable New York Heart Association class². So the benefit was not just a statistical event count — patients reported feeling better and could walk farther.

Two honest caveats sit alongside those numbers. First, the composite benefit was carried by worsening-heart-failure events, not by a reduction in death: cardiovascular deaths were few in both arms (8 on tirzepatide, 5 on placebo), so SUMMIT does not demonstrate that tirzepatide lowers mortality in HFpEF¹. Second, the familiar gastrointestinal side effects showed up: adverse events leading to drug discontinuation occurred in 6.3% of the tirzepatide group versus 1.4% on placebo¹.

The honest part: tirzepatide is NOT FDA-approved for heart failure

This is the line the headlines blur. As of this writing, the FDA prescribing information for Zepbound (tirzepatide) lists exactly two indications: long-term weight management in adults with obesity or overweight with a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity³. Heart failure — HFpEF or otherwise — is not on the label. You cannot get tirzepatide prescribed for heart failure the way you can get it for obesity or sleep apnea.

That does not make the SUMMIT result meaningless — far from it. A single, well-conducted, adequately sized phase 3 trial hitting both of its primary endpoints is exactly the kind of evidence that can support a regulatory filing, and it is reasonable to expect heart-failure benefit to feature in future label or guideline conversations. But "a positive trial exists" and "the FDA has approved this use" are different statements, and only the first is currently true. In practice, if a clinician prescribes tirzepatide to a patient who has both obesity and HFpEF, the on-label reason is the obesity; the heart-failure benefit demonstrated in SUMMIT is a powerful supporting rationale, not an independent approved indication.

It is also worth being precise about which heart failure. SUMMIT studied HFpEF with obesity specifically. It does not establish that tirzepatide helps heart failure with reduced ejection fraction, and it does not speak to HFpEF in people without obesity. Generalizing the result beyond the population that was actually studied is exactly the kind of overreach honest framing is meant to prevent.

Why tirzepatide plausibly helps in HFpEF

The mechanism makes the SUMMIT result coherent rather than surprising. Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces large weight loss — in its pivotal obesity trial, SURMOUNT-1, participants lost roughly 15–21% of body weight at the higher doses⁴. In the obesity phenotype of HFpEF, that weight loss attacks the disease at its root: less body fat means less plasma-volume expansion, less mechanical and inflammatory load on a stiff heart, and reduced congestion. Better blood-sugar handling and lower systemic inflammation point the same way.

So a drug that drives substantial weight loss and improves metabolic health is exactly the kind of agent you would expect to ease an obesity-driven heart-failure syndrome. That coherence is reassuring — and it is also a reminder that much of the benefit likely travels through weight loss, which is why the trial was run in the obese HFpEF population in the first place.

What this means if you have HFpEF

If you have been diagnosed with HFpEF, here is the practical read:

• •Tirzepatide is not an approved heart-failure drug. It is approved for obesity and sleep apnea. A clinician may prescribe it for obesity, and — if you have the obese HFpEF phenotype studied in SUMMIT — your heart failure may benefit too, but that is different from an on-label heart-failure treatment.
• •The SUMMIT data are strong for a specific group: people with HFpEF and obesity. They are the reason this is a serious clinical conversation, not a finished regulatory verdict, and not a result you should extrapolate to other forms of heart failure.
• •It improved events and quality of life, not proven survival. SUMMIT reduced worsening-heart-failure events and improved how patients felt and functioned; it did not demonstrate a mortality benefit.
• •This is a cardiology conversation. Decisions about HFpEF therapy — and whether a weight-loss drug fits into yours — belong with a clinician who can weigh your full picture, including the established HFpEF therapies and the GI tolerability of titrating up to 15 mg.

For the full picture of where tirzepatide's evidence is strong versus still emerging, see our tirzepatide evidence guide. The same "real trial benefit, not yet an approved indication" theme runs through tirzepatide for fatty liver (MASH) and tirzepatide and your kidneys, while the obstructive sleep apnea story is the counter-example — a new indication that did clear the FDA — in our Zepbound for sleep apnea breakdown. For the weight-loss magnitude that underlies the heart-failure benefit, see Zepbound results; to compare how to obtain tirzepatide safely, our best tirzepatide overview.

The honest bottom line

In the SUMMIT trial, tirzepatide cut the risk of cardiovascular death or worsening heart failure to a hazard ratio of 0.62 and improved quality of life and walking distance in 731 patients who had HFpEF with obesity — a real, randomized, phase 3 result on both primary endpoints¹². But tirzepatide is not FDA-approved for heart failure³; SUMMIT studied only the obese HFpEF phenotype, the benefit was driven by fewer heart-failure events rather than fewer deaths, and the result does not extend to other heart-failure types. Until a heart-failure indication is actually granted, the accurate sentence is the careful one: tirzepatide has strong trial evidence for improving outcomes in obesity-related HFpEF, and that is evidence, not an approval.